Regulatory Focus March 24, 2023
By Ferdous Al-Faruque

The US Food and Drug Administration (FDA) plans to hold at least one public meeting and release several guidances on digital health technologies (DHT) to be used in drug clinical trials by the end of the year. While it has issued guidances on digital health products generally, there is still concern about whether such products are accurate and reliable enough to gather data for the drug development process.

As part of FDA’s commitment under the Prescription Drug User Fee Act (PDUFA VII), the agency published a framework on 23 March on how it plans to address long-standing questions on the use of DHTs in drug clinical trials.

The agency has established a steering committee with staff from its drug, device,...

Today's Sponsors


Today's Sponsor


Topics: Clinical Trials, Digital Health, FDA, Govt Agencies, Technology, Trends
AI Models Continue to Gain Clinicians’ Attention
Colon-cancer blood test earns safety endorsement from FDA panel
FDA considers 2nd blood test for colon cancer — but advisers note concerns
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
FDA blesses Pfizer with priority review voucher for Paxlovid nod

Share This Article